{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:46:51Z","timestamp":1791802011878,"version":"4.3.4"},"reference-count":46,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background and Objectives: Neuroendocrine neoplasms (NENs) require multidisciplinary management, yet access to advanced imaging and therapies is uneven across Europe. We aimed to describe real-world management of NENs in an Eastern Europe referral center. Methods: This retrospective single-center study included 192 NEN patients treated between 2011 and 2026 at a national referral center in Romania. Results: Most tumors were well-differentiated (88%), pancreatic primary (59.9%), and non-functioning (77.1%); 51.0% were metastatic at diagnosis. Overall, 30.7% (n = 59) of patients underwent somatostatin receptor imaging, mainly with locally available 99mTc-HYNIC-TOC scintigraphy (n = 56). Among therapeutic modalities, 68.2% of patients underwent conventional systemic therapy and 69.3% had surgery (R0 resection was achieved in 98.9% of curative-intent surgeries; recurrence rate 40%). Peptide receptor radionuclide therapy (PRRT) was performed in 14.6% (19\/130) of metastatic NENs and liver-directed therapy (LDT) in 13.6% (16\/118) of NENs with liver metastases. Median time to treatment was 78 days for somatostatin analogs, 29 days for chemotherapy in neuroendocrine carcinoma, 30 days for surgery, 62.5 days for LDT, and 144 days for PRRT. Conclusions: This is one of the few reports on real-world management of NENs in an Eastern European tertiary care referral center, which highlights the available multidisciplinary care but also the challenges in diagnostics and therapeutic access for patients with NEN.<\/jats:p>","DOI":"10.3390\/jcm15197762","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:40:17Z","timestamp":1791596417000},"page":"7762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidisciplinary Management of Neuroendocrine Neoplasms Beyond Centers of Excellence: Retrospective Real-World Data from a Referral Center in Eastern Europe"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4307-6529","authenticated-orcid":false,"given":"Irina","family":"Sandra","sequence":"first","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Elena Gabriela","family":"Chiorean","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-7194","authenticated-orcid":false,"given":"Irina Mihaela","family":"Cazacu-Croitoru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4708-6265","authenticated-orcid":false,"given":"Vlad Mihai","family":"Croitoru","sequence":"additional","affiliation":[{"name":"Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5275-8938","authenticated-orcid":false,"given":"Simona Olimpia","family":"Dima","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of General Surgery, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Adrian","family":"Goldi\u0219","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Monica","family":"Preda","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Gastroenterology and Hepatology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0608-6565","authenticated-orcid":false,"given":"Rucsandra-Ilinca","family":"Diculescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Gastroenterology and Hepatology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-6570","authenticated-orcid":false,"given":"Adina Emilia","family":"Croitoru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Mircea Mihai","family":"Diculescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Gastroenterology and Hepatology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e220097","DOI":"10.1530\/EC-22-0097","article-title":"Management of neuroendocrine neoplasms: Conformity with guidelines in and outside a center of excellence","volume":"11","author":"Morin","year":"2022","journal-title":"Endocr. Connect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100478","DOI":"10.1016\/j.esmoop.2022.100478","article-title":"Pulmonary neuroendocrine tumours and somatostatin receptor status: An assessment of unlicensed use of somatostatin analogues in the clinical practice","volume":"7","author":"Kiesewetter","year":"2022","journal-title":"ESMO Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e13310","DOI":"10.1111\/jne.13310","article-title":"Global challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients","volume":"35","author":"Dureja","year":"2023","journal-title":"J. Neuroendocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e240053","DOI":"10.1530\/EO-24-0053","article-title":"Radioembolization for neuroendocrine tumors: Procedure, application and clinical outcomes","volume":"5","author":"Ho","year":"2025","journal-title":"Endocr. Oncol."},{"key":"ref_6","unstructured":"ENETS (2026, August 06). Find an ENETS CoE. Available online: https:\/\/www.enets.org\/list-of-coes.html."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Diculescu, R.-I., Stroie, T., Istr\u0103tescu, D., Croitoru, A.E., Gheorghe, C., Bra\u0219oveanu, V., Dumitra\u0219cu, T., Eftimie, M.A., \u021au\u021buian, R., and Poian\u0103, C. (2025). Clinical Management and Prognostic Outcomes of Pancreatic Neuroendocrine Tumors: Insights from a Tertiary Care Center. Medicina, 61.","DOI":"10.3390\/medicina61111955"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2515798","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of Neuroendocrine Neoplasms in the US","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Brierley, J.D., Gospodarowicz, M.K., and Wittekind, C. (2017). TNM Classification of Malignant Tumours, John Wiley & Sons.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gherghe, M., Laz\u0103r, A.M., Stanciu, A.E., Mutuleanu, M.-D., Sterea, M.-C., Petroiu, C., and Gale\u0219, L.N. (2022). The New Radiolabeled Peptide 99mTcEDDA\/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs?. Cancers, 14.","DOI":"10.3390\/cancers14112725"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Nikou, G.C., Pazaitou-Panayiotou, K., Dimitroulopoulos, D., Alexandrakis, G., Papakostas, P., Vaslamatzis, M., Kaldrymidis, P., Markussis, V., and Koumarianou, A. (2016). Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. BMC Endocr. Disord., 16.","DOI":"10.1186\/s12902-016-0089-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e70220","DOI":"10.1111\/jne.70220","article-title":"Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers","volume":"38","author":"Deroose","year":"2026","journal-title":"J. Neuroendocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s002590050556","article-title":"Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: First results in patients and comparison with 111In-DTPA-D-Phe1-octreotide","volume":"27","author":"Bangard","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Perrone, E., Treglia, G., Giancipoli, R.G., Leccisotti, L., Rindi, G., and Rufini, V. (2025). In Vivo Versus In Vitro Somatostatin Receptor Expression in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Correlation Studies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146551"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1055\/a-2159-5548","article-title":"Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis","volume":"55","author":"Mathew","year":"2023","journal-title":"Horm. Metab. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Slott, C., Langer, S.W., M\u00f8ller, S., Krogh, J., Klose, M., Hansen, C.P., Kjaer, A., Holmager, P., Garbyal, R.S., and Knigge, U. (2024). Outlook for 615 Small Intestinal Neuroendocrine Tumor Patients: Recurrence Risk after Surgery and Disease-Specific Survival in Advanced Disease. Cancers, 16.","DOI":"10.3390\/cancers16010204"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lenotti, E., Alberti, A., Spada, F., Amoroso, V., Maisonneuve, P., Grisanti, S., Baggi, A., Bianchi, S., Fazio, N., and Berruti, A. (2021). Outcome of Patients with Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy with Somatostatin Analogs. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.669484"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00330-024-11095-7","article-title":"ESR Essentials: Role of PET\/CT in neuroendocrine tumors\u2014Practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging","volume":"35","author":"Ebner","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Schmidt, M., Hinterleitner, C., Singer, S., Lauer, U.M., Zender, L., and Hinterleitner, M. (2023). Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance\u2014A Retrospective, Long-Term Single-Center Experience. Cancers, 15.","DOI":"10.3390\/cancers15174316"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00432-025-06126-9","article-title":"Patterns and outcomes of current antitumor therapy for high-grade neuroendocrine neoplasms: Perspective of a tertiary referral center","volume":"151","author":"Melhorn","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e13423","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J. Neuroendocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.36469\/jheor.2023.89300","article-title":"Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors","volume":"10","author":"Clarke","year":"2023","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e13146","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease","volume":"34","author":"Davar","year":"2022","journal-title":"J. Neuroendocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.21037\/tcr-23-2215","article-title":"Development and validation of a nomogram to predict overall survival of gastroenteropancreatic neuroendocrine carcinoma: A SEER database analysis","volume":"13","author":"Chen","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/ijc.32678","article-title":"Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals","volume":"146","author":"Leyden","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S756","DOI":"10.1016\/j.annonc.2024.08.1216","article-title":"1157P Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry","volume":"35","author":"Cubero","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Nair, G., Black, M., Baer, K., Welch, S., Laidley, D.T., Goodwin, R., Leung, M., Phillips, W.J., Vickers, M., and Asmis, T. (2025). Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32020086"},{"key":"ref_30","unstructured":"(2026, June 04). Delays in the Dosing Administration of PRRT in Advanced Neuroendocrine Tumors\u2014Is There an Adverse Impact?. Available online: https:\/\/my.enets.org\/abstracts.4114.html."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e13138","DOI":"10.1111\/jne.13138","article-title":"Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours","volume":"34","author":"Almeamar","year":"2022","journal-title":"J. Neuroendocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4518742","DOI":"10.1155\/2019\/4518742","article-title":"Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism","volume":"2019","author":"Santos","year":"2019","journal-title":"Int. J. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","article-title":"Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database","volume":"24","author":"Fairweather","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Clift, A.K., Drymousis, P., von Roon, A., Humphries, A., Goldin, R., Bomanji, J., Leaman, S., Wasan, H., Habib, N., and Frilling, A. (2023). Management of Small Bowel Neuroendocrine Tumours: 10 Years\u2019 Experience at a Tertiary Referral Centre. Cancers, 15.","DOI":"10.3390\/cancers15184438"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Armellini, E., Facciorusso, A., and Crin\u00f2, S.F. (2023). Efficacy and Safety of Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neuroendocrine Tumors: A Systematic Review and Metanalysis. Medicina, 59.","DOI":"10.3390\/medicina59020359"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e16317","DOI":"10.1200\/JCO.2026.44.16_suppl.e16317","article-title":"Real-world evidence of response to 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) based on primary and metastatic sites in patients (pts) with neuroendocrine tumor (NET)","volume":"44","author":"Shah","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kenney, L.M., and Hughes, M. (2025). Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 17.","DOI":"10.3390\/cancers17030377"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00268-015-3328-6","article-title":"Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review","volume":"40","author":"Jilesen","year":"2016","journal-title":"World J. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1245\/s10434-014-3728-0","article-title":"Pancreastatin Predicts Survival in Neuroendocrine Tumors","volume":"21","author":"Sherman","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s13304-024-01942-z","article-title":"Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: A retrospective cohort from a high-volume center","volume":"76","author":"Paiella","year":"2024","journal-title":"Updat. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MPA.0000000000001791","article-title":"Recurrence Patterns Following Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis from the National Comprehensive Cancer Network Oncology Outcomes Database","volume":"50","author":"Chan","year":"2021","journal-title":"Pancreas"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/SLA.0000000000005809","article-title":"Recurring Pancreatic Neuroendocrine Tumor: Timing and pattern of recurrence, and current treatment","volume":"278","author":"Pulvirenti","year":"2023","journal-title":"Ann. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.3390\/curroncol30080544","article-title":"Small Bowel Neuroendocrine Tumors\u201410-Year Experience of the Ottawa Hospital (TOH)","volume":"30","author":"Alfagih","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17588359221138389","DOI":"10.1177\/17588359221138389","article-title":"Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: Real-world data from the Medical University of Vienna","volume":"14","author":"Melhorn","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_46","first-page":"e1462","article-title":"The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study","volume":"5","author":"Lea","year":"2022","journal-title":"Cancer Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7762\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:08:12Z","timestamp":1791799692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":46,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197762"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197762","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}